GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LianBio (OTCPK:LIANY) » Definitions » Cash Ratio

LianBio (LianBio) Cash Ratio : 9.84 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LianBio Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. LianBio's Cash Ratio for the quarter that ended in Sep. 2023 was 9.84.

LianBio has a Cash Ratio of 9.84. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for LianBio's Cash Ratio or its related term are showing as below:

LIANY' s Cash Ratio Range Over the Past 10 Years
Min: 3.39   Med: 12.87   Max: 40.85
Current: 9.84

During the past 4 years, LianBio's highest Cash Ratio was 40.85. The lowest was 3.39. And the median was 12.87.

LIANY's Cash Ratio is ranked better than
80.57% of 1508 companies
in the Biotechnology industry
Industry Median: 2.955 vs LIANY: 9.84

LianBio Cash Ratio Historical Data

The historical data trend for LianBio's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LianBio Cash Ratio Chart

LianBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Ratio
12.94 40.85 25.39 12.80

LianBio Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.15 12.80 11.05 12.35 9.84

Competitive Comparison of LianBio's Cash Ratio

For the Biotechnology subindustry, LianBio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LianBio's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LianBio's Cash Ratio distribution charts can be found below:

* The bar in red indicates where LianBio's Cash Ratio falls into.



LianBio Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

LianBio's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=302.363/23.615
=12.80

LianBio's Cash Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash Ratio (Q: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=252.222/25.627
=9.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LianBio  (OTCPK:LIANY) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


LianBio Cash Ratio Related Terms

Thank you for viewing the detailed overview of LianBio's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


LianBio (LianBio) Business Description

Traded in Other Exchanges
N/A
Address
103 Carnegie Center Drive, Suite 215, Princeton, NJ, USA, 08540
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Wei Wei Chen director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON NJ 08540
Debra Yu officer: See Remarks C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
C2 Life Sciences Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Lev Lb Holdings Gp, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Venture Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Brianne Jahn officer: Chief Business Officer C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Yizhe Wang director, officer: Chief Executive Officer 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Jiang Qian officer: China General Manager C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lev Lb Holdings, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Xontogeny Venture Fund, Lp 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Yi Larson officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Neil Kumar director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304

LianBio (LianBio) Headlines

From GuruFocus

LianBio Announces President and Chief Strategy Officer Departure

By GlobeNewswire GlobeNewswire 12-13-2022

LianBio Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024

LianBio at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-07-2024